Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech ...
In the coming weeks, Quantum Biopharma will seek FDA permission for a clinical trial testing Lucid-MS, its therapy to slow myelin loss in MS.
Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...
A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...
Detailed price information for Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM-CN) from The Globe and Mail including charting and trades.
Detailed price information for Quantum Biopharma Ltd (QNTM-Q) from The Globe and Mail including charting and trades.
Stocktwits on MSN
Why did QNTM stock pop in pre-market today?
Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding ...
Latest News and Articles on Multiple sclerosis. Read stories and expert opinion articles on Multiple sclerosis at ...
The treatment of multiple sclerosis (MS) has improved dramatically over the past two decades thanks to the advent of a second generation of immunomodulatory therapies. They have significantly reduced ...
Gliogenesis is the developmental process by which glial cells – astrocytes, oligodendrocytes, Schwann cells, microglia – are generated. It includes the production of glial progenitor cells and their ...
Researchers from the Cyprus Institute of Neurology and Genetics and collaborators report the development of a gene silencing therapy for Charcot-Marie-Tooth type 1A.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results